US FDA approve Factive for cystitis indication

LG Life Sciences says that the United States Food and Drug Administration (FDA) approved its additional efficacy supplement for Factive (gemifloxacin mesylate) to treat cystitis, in adidition to mild-to-moderate community- acquired pneumonia (CAP) due to multi-drug resistant Streptococcus pneumoniae (MDRSP).

In April 2003, Factive received FDA approval for the treatment of mild-to-moderate ...